A Phase 4 interventional study of Nicorandil in No-Reflow Phenomenon, Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by Korea University Anam Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Korea University Anam Hospital · Phase 4, Interventional, and Prevention
The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden index in patients with coronary artery disease who require stent treatment.
Exclusion Criteria:
If the lipid core burden index at the main lesion site on vascular ultrasound exceeds 353, randomization was performed. Nicorandil group will be administrated 8cc or more of the prescribed drug (Nicroandil) according to randomization into the coronary artery before starting balloon therapy.
Drug: Nicorandil
If the lipid core burden index at the main lesion site on vascular ultrasound exceeds 353, randomization was performed. Standard PCI group will be performed coronary intervention including starting balloon therapy without pre-administrated nicorandil.
Administer 8cc or more of the prescribed drug according to randomization into the coronary artery before starting balloon therapy. The stent treatment method follows the standard treatment method.
Occurrence of decreased TIMI flow
occurrence of decreased TIMI flow (0,1,2) during the index procedure Grade 0-No perfusion Grade 1-Penetration without perfusion Grade 2-Partial perfusion but not reach complete perfusion Grade 3-Complete perfusion;; antegrade flow into the bed distal to the obstruction occurs as promptly as antegrade flow into the bed proximal to the obstruction, and clearance of contrast material from the involved bed is as rapid as clearance from an uninvolved bed in the same vessel or the opposite artery.
Time frame: during procedure
Change of cardiac biomarker level after intervention
level change of CPK
Time frame: 1 month
Change of cardiac biomarker level after intervention
level change of CK-MB
Time frame: 1 month
Change of cardiac biomarker level after intervention
level change of Troponin T
Time frame: 1 month
Change of cardiac biomarker level after intervention
level change of Troponin I
Time frame: 1 month
patient-oriented composite end point
composite of all cause mortality, any myocardial infarction, and any revascularization
Time frame: 1 year
Percentage of All cause mortality
Time frame: 1 year
Percentage of cardiac death
Time frame: 1 year
Percentage of myocardial infarction
Time frame: 1 year
Percentage of revascularization
Time frame: 1 year
Association between lipid profile and lipid core burden index
Correlation among LDL-cholesterol, lipoprotein(a), pre-procedural LCBi max, Post-procedural LCBi, LCBi total burden
Time frame: 6 month
Plan to share: No — The data generated in this study is available from the corresponding author(s) upon reasonable request.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Korea University Anam Hospital